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Abstract
Background— Pulmonary arterial hypertension (PAH) is a heterogeneous disorder with high
mortality. 
Methods—We conducted a comprehensive study of plasma metabolites using ultra-performance 
liquid chromatography mass-spectrometry to (1) identify patients at high risk of early death, (2) 
identify patients who respond well to treatment and (3) provide novel molecular insights into 
disease pathogenesis.
Results— 53 circulating metabolites distinguished well-phenotyped patients with idiopathic or 
heritable PAH (n=365) from healthy controls (n=121) following correction for multiple testing 
(p<7.3e-5) and confounding factors, including drug therapy, renal and hepatic impairment. A 
subset of 20/53 metabolites also discriminated PAH patients from disease controls (symptomatic 
patients without pulmonary hypertension, n=139). 62 metabolites were prognostic in PAH, with 
36/62 independent of established prognostic markers. Increased levels of tRNA-specific 
modified nucleosides (N2,N2-dimethylguanosine, N1-methylinosine), TCA cycle intermediates 
(malate, fumarate), glutamate, fatty acid acylcarnitines, tryptophan and polyamine metabolites 
and decreased levels of steroids, sphingomyelins and phosphatidylcholines distinguished patients 
from controls. The largest differences correlated with increased risk of death and correction of 
several metabolites over time was associated with a better outcome. Patients who responded to 
calcium channel blocker therapy had metabolic profiles similar to healthy controls. 
Conclusions— Metabolic profiles in PAH are strongly related to survival and should be 
considered part of the deep phenotypic characterisation of this disease. Our results support the 
investigation of targeted therapeutic strategies that seek to address the alterations in translational 
regulation and energy metabolism that characterise these patients.  
Key-words: metabolome; metabolomics; metabolism; pulmonary circulation; pulmonary 
hypertension 
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Clinical Perspective
What is new? 
? This study provides a comprehensive analysis of circulating metabolite levels in patients
with pulmonary arterial hypertension (PAH) and controls.
? It is the first to relate metabolite levels to clinical outcomes in PAH.
? Increases in circulating modified nucleosides originating from transfer RNAs, energy
metabolism intermediates, tryptophan and polyamine metabolites, and decreased steroids,
sphingomyelins and phosphatidylcholines independently discriminate PAH patients from
controls and predict survival.
? Correction of metabolite levels over time is linked to better clinical outcomes and
patients who respond well to calcium-channel blocker therapy have metabolic profiles
comparable with healthy controls.
What are the clinical implications?
? Energy metabolism and stress-response pathways are disturbed in PAH.
? Monitoring plasma metabolites that report on these pathways over time could be useful to
assess disease progression and response to therapy.
? Therapeutic strategies targeted against metabolic disturbances in PAH, particularly
translational regulation and energy metabolism, merit further investigation
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Introduction
Pulmonary arterial hypertension (PAH) is a progressive vascular disorder that leads to increased 
pulmonary vascular resistance, right ventricular (RV) dysfunction 1 and premature death 2. The 
pathogenesis of the vascular pathology is poorly understood 3, 4. Several genetic mutations have 
been reported in hereditary and isolated idiopathic presentations of PAH, providing insight into 
perturbed signalling pathways 5, 6, and genome sequencing of clinically well characterised patient 
cohorts is underway in anticipation of finding new mutations. A complementary approach to 
identifying the molecular drivers of PAH is to conduct deep molecular phenotyping of patients 
beyond standard clinical tests.
Metabolomic technologies, such as ultra-performance liquid chromatography mass spectrometry, 
enable the detection and semi-quantitative measurement of hundreds of unique metabolites, 
representing a broad range of metabolic pathways, in small volumes of biofluids 7. These 
approaches have identified differences in circulating metabolites that distinguish physiological 
and disease states, such as diabetes and systemic cardiovascular disorders, and predict clinical 
outcomes 8-10. As yet, few metabolomics studies have been undertaken in patients with 
pulmonary vascular disease.  Evidence of abnormal oxidation, arginine and sphingosine 
pathways have been found from mass spectrometry analysis of lung tissue from PAH patients 11, 
12 and analysis of breath samples showed exhaled volatile compounds discriminate between 
severe idiopathic PAH and healthy volunteers 13. A targeted analysis of 105 circulating plasma 
metabolites in PAH, primarily amino acids, nucleosides and their derivatives, showed abnormal 
levels of tryptophan, purine and tricarboxylic acid cycle metabolites correlated to haemodynamic 
measures 14.
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In this study, we used a broad metabolomics platform to analyse 1416 metabolites in plasma 
from patients with idiopathic or heritable PAH (n=365) in three distinct cohorts and compared 
circulating levels with both healthy (n=121) and disease controls (n=139). We identified specific 
metabolites that both discriminate PAH patients from healthy and disease controls and 
independently predict survival. These metabolites included several modified nucleosides specific 
to transfer RNAs that indicate alterations in cell proliferation and translation of disease-related 
proteins as well as several constituents of energy metabolism.
Methods 
Sample collection
Samples were obtained from patients with idiopathic or heritable PAH attending the National 
Pulmonary Hypertension Service at Hammersmith Hospital, London between 2002-2015 and 
from patients recruited from other UK national centres as part of the National Cohort Study of 
Idiopathic and Heritable Pulmonary Arterial Hypertension (ClinicalTrials.gov NCT01907295). 
Control plasma samples were obtained from healthy subjects and disease controls, the latter 
being symptomatic patients presenting to the service but in whom pulmonary hypertension was 
excluded by cardiac catheterisation. The diagnosis of PAH was based on standard criteria from 
the most recent guidelines 1. Vasoresponders were defined as those who dropped their mean 
pulmonary artery pressure >10 mmHg to <40 mmHg, with preserved cardiac output, in response 
to an acute pulmonary vasodilator challenge and remained stable on calcium channel blocker 
therapy alone for at least 1 year 1. Whole-genome sequencing data from the UK National 
Institute of Health Research Biomedical Research Centres Inherited Diseases Genetic Evaluation 
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(BRIDGE) consortium were used to determine which patients had known pathogenic mutations 
in the gene encoding the bone morphogenetic protein type II receptor (BMPR2) 5.
Venous blood samples were drawn from the antecubital fossa and collected in EDTA 
Vacutainer tubes (BD, Oxford, UK), immediately put on ice, centrifuged (1,300g, 15 minutes) 
within 30 minutes and stored at -80?C until required.  WHO functional class and six minute walk 
distance at sample date and clinical biochemical data (within 30 days) were recorded. All 
subjects provided informed written consent and local research ethics committees approved the 
study. A subset of patients consented to provide additional samples at later dates whilst attending 
follow-up clinical appointments.
Metabolomics 
Metabolomic profiling by ultra-performance liquid chromatography mass spectrometry was 
conducted by Metabolon (Durham, NC, USA) 7, who provided semi-quantitative assessment of 
949 named and 467 unnamed metabolite levels, annotated with pathways. Named compounds 
identified based on mass and fragmentation analysis but yet to be confirmed with standards are 
indicated by asterisks. Details can be found in the supplementary materials. 
Angiogenin 
Plasma angiogenin levels were determined by ELISA (Ref:DAN00, R&D Systems, Abingdon, 
UK) as per manufacturer’s guidelines, with EDTA plasma diluted 1:800 before assay. 
Statistical Analysis
To prevent skewing of results by outliers, initial group comparisons between controls and 
patients were performed using non-parametric Mann Whitney U tests. Prior to modelling, 
metabolites whose distribution was not normal were transformed either by log10 or power 
transformations (xY, with Y from -2 to 2 in 0.5 steps, as performed for Box-Cox transformations 
 by guest on D
ecem
ber 7, 2016
http://circ.ahajournals.org/
D
ow
nloaded from
 
10.1161/CIRCULATIONAHA.116.024602
7 
15), whichever best normalised the data based on Kolmogorov-Smirnov tests, or ranked if no test 
met p>0.05. Samples where metabolites were undetected were imputed with the minimum 
detected level for the metabolite. Data in all groups were z-score transformed based on the mean 
and standard deviation in all healthy controls for ease of comparisons. Data are presented as 
absolute numbers, percentages, mean or median (±standard deviation, SD) and percentile range.  
Linear regression analysis was conducted to assess the relationships between metabolite levels, 
diagnoses and potential confounders to determine whether differences in metabolite levels 
between groups was independent of age, gender, ethnicity, body mass index, drugs, renal and 
hepatic dysfunction. In the disease control and PAH cohorts, preserved renal function was 
defined as creatinine <75 μmol/L, and liver function as bilirubin <21 μmol/L. Logistic regression 
was conducted to determine metabolites that independently distinguished between diagnostic 
groups. Orthogonal partial least squares discriminant analysis (OPLS-DA) modelling was used to 
test the performance of these metabolites. R2 scores indicate model performance and Q2 scores 
estimate reproducibility, based on cross validation (subjects were divided into 7 groups and their 
diagnosis was predicted based on the other subjects in seven analyses). Pathway enrichment 
analysis was conducted on discriminating and prognostic metabolites using Fisher’s exact test. 
All survival analyses were performed using time from sampling to death/census. Cox regression 
analysis was used to identify prognostic predictors, with proportional hazard assumptions tested 
and Kaplan-Meier plots used to illustrate events from time of sampling in relation to metabolite 
levels. Receiver Operating Characteristic (ROC) curves were used to assess discriminating and 
prognostic value of metabolites against diagnosis and all-cause mortality respectively. 
Hierarchical clustering based on Euclidean distances was used to assess if metabolites and 
patients clustered by functional pathways and phenotypes, respectively. 
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Network analysis was performed by calculating second order Spearman’s rank correlations using 
ParCorA 16, 17 and visualised using Cytoscape 18. ‘Hub’ nodes are metabolites with the most 
‘edges’ (correlations) to other metabolites.
Statistical analysis was performed using IBM SPSS Statistics 22 (International Business 
Machines Corporation, New York, USA), Matlab (Matrix Laboratory, MathWorks, Natick, 
Massachusetts, USA), Microsoft Excel (Microsoft, Redmond, Washington, USA), SIMCA-P
software, (Umetrics, Umea, Sweden) and R with RStudio and associated packages 19.  
Results
Metabolites distinguishing between PAH and controls
We first compared plasma metabolite profiles from 116 consecutive patients with idiopathic or 
heritable PAH attending Hammersmith Hospital between November 2011 and August 2013 and 
58 healthy controls (Table 1). To minimise confounding factors, only PAH patients aged 19-70 
were compared with age- and sex-matched healthy controls in this analysis. Results were 
validated in 75 PAH patients recruited between 2002 and 2015 against a separate control group 
(n=63). A second validation analysis used 174 PAH patients recruited from other specialist 
centres in the UK from August 2013 to June 2015 and compared to all controls. Metabolites 
identified as xenobiotics or detected in less than 95% of samples were excluded from the 
analysis, leaving 686 well-quantified biological metabolites.
Circulating levels of 97 metabolites distinguished PAH from healthy subjects in all three 
analyses following Bonferroni correction (p<7.3e-5). Of these metabolites, 53 distinguished 
healthy and PAH subjects after correcting for potential confounders, including age, gender, 
ethnicity, body mass index, creatinine, bilirubin and drug therapies (p<0.05, Table S1, Fig. 1). 
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The most common confounders associated with metabolite levels were liver function (bilirubin) 
and renal function (creatinine). To determine whether these metabolite differences could be 
detected prior to initiation of PAH therapies, we performed a sub-analysis comparing 40 patients 
who were treatment naïve at the time of sampling and all 53 metabolites distinguished this group 
from healthy controls (p<0.05, Table S1). Patients with pathogenic BMPR2 mutations (n=42) 
had similar metabolite levels to PAH patients without these mutations (Fig. S1, Table S1).
Given that many metabolic alterations might occur in a chronic disease such as PAH, we set out 
to prioritise more disease-specific metabolites by comparing the PAH patients with disease 
controls, the latter comprising symptomatic patients in whom pulmonary hypertension had been 
excluded. We again adopted a discovery and validation design, with two groups of disease 
controls (n=70 and 69). A subset (20/53) of the metabolites distinguished PAH patients from 
disease controls after correcting for potential confounders (p<0.05, Table S1). These ‘PAH-
specific’ differences in metabolites included increases in purine, polyamine and tricarboxylic 
acid (TCA) cycle metabolites, and decreases in phosphocholines and sphingomyelins (Fig. 2A), 
with network analysis showing the importance of ‘hub’ metabolites N2,N2-dimethylguanosine 
and malate (Fig. 2B). 
Discriminant analyses to distinguish PAH and control groups 
To identify a minimal set of metabolites which could in combination best distinguish PAH 
patients, we performed logistic regression analysis. We found 7/53 metabolites – 
dehydroisoandrosterone sulfate (DHEA-S), methionine sulfone, N1-methylinosine, 
oleoylcarnitine, palmitoylcholine, sphingomyelin (d18:1/20:0, d16:1/22:0)* and X-24513 – 
independently distinguished PAH (aged 19-70) and healthy subjects in the discovery analysis, 
with 90% accuracy in an orthogonal partial least squares discriminant analysis (OPLS-DA, 
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R2=0.64, Q2=0.61). This model classified healthy and PAH subjects in the two validation 
analyses with 89% and 84% accuracy, respectively. In addition, 90% (9/10) of PAH 
vasoresponders in the discovery cohort had metabolite levels typical of healthy controls (Fig. 
3A-B).
Out of the 20 ‘PAH-specific’ metabolites, four – N-acetylaspartate, octadecanedioate, 
palmitoylcholine and X-13737 – distinguished PAH patients and disease controls with 83% 
accuracy in the discovery analysis (R2=0.49, Q2=0.47).  This model classified disease controls 
and PAH subjects in the two validation analyses with 69% and 67% accuracy, respectively (Fig. 
3C-D).
Survival analysis of plasma peaks of interest in PAH 
We hypothesised that metabolites most closely related to the disease pathobiology would be 
associated with clinical outcomes. To identify metabolites associated with disease progression 
and mortality, we performed survival analyses. 28/116 and 25/75 patients died in the discovery 
and first validation PAH groups, with an average follow-up of 3.3±1.0 and 4.5±4.0 years, 
respectively. The length of patient follow-up in the second validation cohort was insufficient to 
permit analysis. After controlling for creatinine and diuretic use, no other potentially 
confounding factor was associated with survival. Of the 686 well-quantified metabolites, 640 
met the assumptions of Cox regression analysis, and 62 of these were prognostic after accounting 
for creatinine and diuretic use in both analyses. ROC analysis at 3 years of follow-up confirmed 
these metabolites were prognostic and identified optimal cut-offs (Fig. S2, p<0.05).  
To identify metabolites that report on novel pathways independent of current prognostic 
estimates, we compared the 62 prognostic metabolites with three markers previously found to 
best predict survival in our patients – namely, N-terminal brain natriuretic peptide (NT-proBNP), 
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six minute walk distance (6MWD) and red cell distribution width (RDW) 20. 36/62 of the 
metabolites were independent of these measures (p<0.05, Fig. 4A, Table S2) and network 
analysis indicated two main clusters with ‘hub’ metabolites including again, among others, 
N2,N2-dimethylguanosine (Fig. 4B).  
Enrichment and clustering of metabolites of interest
The above analyses identified and validated, after controlling for confounders, a total of 100 
metabolites that were either discriminating or prognostic in PAH, representing twenty five 
metabolic pathways. Six pathways in particular were enriched with metabolites of interest, 
including fatty acid (acyl carnitines), polyamine and nucleoside metabolism (Table S3, p<0.05). 
Sixteen of these metabolites both discriminated PAH and were prognostic; these, along with the 
three other metabolites which were selected by logistic regression modelling to best distinguish 
PAH and healthy subjects, clustered into defined metabolic pathways (Fig. 5).  
Analysis of serial samples 
Changes in metabolite levels in individuals over time may indicate pathways that report clinical 
improvement or whose correction itself leads to improved outcomes. We analysed serial samples 
from 86 patients who were followed up for a minimum of 1 year (median 1.50, interquartile 
range 1.33-2.95 years) after the second sample. Twenty nine patients died during follow-up. 
Changes in metabolite levels between the two samples (median time between samples 1.75, IQR 
1.07-2.58 years) were compared between ‘survivors’ and ‘non-survivors’. 
Changes in 27/100 metabolites were significantly different between survivors and non-survivors 
(p<0.05), including several modified amino acids and nucleosides. ROC analysis confirmed 
these associations (Table S4) and identified prognostic cut-offs (Fig. 6).
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Association of elevated modified nucleosides with elevated plasma angiogenin 
Modified nucleosides can be released into the circulation during stress following cleavage of 
tRNAs by the ribonuclease angiogenin 21. To determine whether this mechanism was relevant to 
PAH, we measured plasma angiogenin in a representative subset of age- and sex-matched 
healthy controls and PAH patients from the discovery analysis (Table S5). Angiogenin levels 
were elevated in plasma from PAH patients and correlated with N2,N2-dimethylguanosine levels 
(Rho:0.49, p<0.001, Fig. 7). The strength of correlation was similar in male and female subjects 
(data not shown). 
Discussion
This study represents the most comprehensive analysis of circulating metabolites in patients with 
PAH to date. It is the first to robustly identify and validate differences in comparison to both 
healthy and symptomatic disease controls without pulmonary hypertension, and to associate 
metabolic profiles with outcomes in PAH, strengthening the evidence that the pathways 
identified could be important modifiers of disease progression. Changes in the levels of 
metabolites over time were associated with survival in a direction that suggests that correction of 
these disturbances is linked to improved outcomes. In agreement with this, patients defined as 
vasoresponders, who have excellent outcomes on calcium channel blocker therapies, 
demonstrated metabolic profiles more similar to healthy controls than other patients. Metabolic 
profiles seen in incident cases were similar to those with established PAH, emphasising that 
metabolic dysregulation is not corrected in the majority of cases by current therapy. 
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Modified nucleosides 
Two of the most robust distinguishing and prognostic differences identified in PAH patients 
were increased levels of N1-methylinosine and N2,N2-dimethylguanosine. These are recognised 
epigenetic, post-transcriptional modifications of transfer RNA (tRNA) 21-23, and other tRNA 
modifications also found to be increased and prognostic included pseudouridine, N6-
carbamoylthreonyladenosine and N1-methyladenosine. N2,N2-dimethylguanosine is found in the 
majority of tRNAs at position 26, upstream of the anticodon sequence at positions 34-36, and 
promotes the folding of tRNAs towards the classical clover-leaf structure 24. N1-methylinosine is 
found 3' adjacent to the anticodon at position 37 of eukaryotic tRNAs and is formed from inosine 
by a specific S-adenosylmethionine-dependent methylase 25. Increased serum and urine levels of 
N2,N2-dimethylguanosine, as well as pseudouridine and 1-methylinosine, have been observed in 
multiple solid tumour malignancies 26 and may reflect the general upregulation of the 
translational apparatus, including tRNA turnover, in hyperproliferative cancerous cells 27.
Increased circulating 1-methyladenosine has also been shown to be an early indicator of 
oxidative stress, cell damage and mortality in kidney disease 28.
 Intracellular tRNA pools are dynamically regulated. For example under stress, tRNAs 
required for the translation of stress response proteins are preferentially expressed 21. The altered 
levels of specific nucleoside modifications in PAH patients may reflect preferential expression of 
tRNAs that harbour them, as part of a switch towards translation of disease-related proteins. In 
addition, stress-induced cleavage of tRNA produces fragments that propagate the stress response 
and interfere with eukaryotic initiation factor (eIF)-4G and eIF4F21???????????????????????????-4 
????????????????????????????????????????????????????????????? ??-tRNA, suppressing general 
protein synthesis and activating stress-inducible transcription factors, is mutated and causally 
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implicated in some cases of pulmonary vascular disease 29. Mutations in tRNA genes themselves 
have also been reported to cause pulmonary hypertension driven by mitochondrial dysfunction 30.
The initial cleavage of tRNAs is mediated by angiogenin 21, which we showed to be 
elevated in the plasma of PAH patients in concert with elevated levels of modified nucleosides. 
Angiogenin is also upregulated in cancer cells, mediating angiogenesis, cell proliferation and 
protection from apoptosis 31, and is increased in breath condensates from patients with 
pulmonary hypertension 32, indicating a possible pulmonary origin in this disease. 
Angioproliferative plexiform vascular lesions are characteristic of advanced PAH and the pro-
angiogenic activity of angiogenin is inhibited by mutation of its ribonuclease active site 33,
suggesting that elevated angiogenin and nucleoside levels may report patients developing this 
type of pulmonary vascular remodelling. Alterations in tRNA biology appear to be capable of 
driving the development of rare forms of pulmonary hypertension and are closely linked to the 
progression of PAH, and circulating levels of modified nucleosides may reflect increases in both 
pulmonary vascular cell proliferation and stress.  
Energy metabolism 
Significant alterations were observed in several pathways related to cellular energy production, 
with accumulation of multiple acylcarnitines, glutamate and TCA cycle intermediates. Their 
accumulation in PAH patients may represent a failed attempt to increase utility of fatty acids as 
an energy source, perhaps reflecting the inability of fatty acid beta-oxidation to keep pace with 
the demands of the overburdened right ventricle. Glutaminolysis is another alternative energy 
production pathway to glucose oxidation, with the product glutamate entering the TCA cycle as 
?-ketoglutarate.  Inhibition of glutaminolysis and restoration of glucose oxidation has beneficial 
effects in rat models of right ventricular hypertrophy 34. Increased circulating glutamate levels 
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have previously been seen in cancer patients 35, however, anti-glutaminolysis therapeutic targets 
have demonstrated toxic side effects 36. The build-up of TCA intermediates and the precursors to 
the molecules that enter the cycle (acylcarnitines and glutamate) may indicate dysfunction of this 
cycle, or at least the inability to keep pace with the demands of the most active cells, such as 
proliferating pulmonary vascular cells. Increased levels of citrate, succinate and fatty acid 
metabolites have been demonstrated in lung tissue from PAH patients 11, suggesting 
dysfunctional energy metabolism is a feature of the diseased tissue. Restoration of glucose 
oxidation by dichloroacetate therapy is under investigation as a treatment for PAH 37, and 
maximising the capacity of the TCA cycle to process the acetyl-CoA produced may be a 
complementary therapeutic approach.  
Consistent with previous reports we found a significant increase in the circulating levels 
of long-chain acylcarnitines (oleoylcarnitine) 38, and also short- (myristoylcarnitine, 
acetylcarnitine, hydroxbutyrylcarnitine) and medium- (adipoylcarnitine, suberoylcarnitine) chain 
products.  The accumulation of acylcarnitines may itself be detrimental, effecting cardiac 
electrophysiological changes and arrhythmias 39. There is also increasing evidence that 
accumulation of long chain acylcarnitines may contribute to insulin resistance 40, which is itself 
common and associated with prognosis in PAH 41.
Lipids, steroids, polyamines and tryptophan metabolites 
Multiple sphingomyelin and phosphatidylcholine lipid species were significantly reduced in 
PAH patients, relating to increased mortality. Sphingomyelins are the most abundant subclass of 
sphingolipids, with other subclasses including sphinogosines, ceramides and glycophospholipids 
42. In patients with chronic obstructive pulmonary disease (COPD), low plasma levels of several
sphingomyelins relate to disease severity 43. As a membrane constituent, sphingomyelins are 
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implicated in trans-membrane signalling and are generated from phosphatidylcholine and 
ceramide by sphingomyelin synthase, knockout of which leads to mitochondrial dysfunction and 
reduced insulin release 44. Sphingomyelins may also be considered a source of ceramide, which 
directly (and indirectly through other active lipid products) regulates cell proliferation, apoptosis, 
cell migration and autophagy 45.
Reduced lineoyl-GPC has been shown to be an early marker of insulin resistance in non-
diabetics 46, and decreased circulating levels of several phosphatidylcholines were seen in 
patients with severe heart failure 47. Phospholipids are also sources of multiple cellular signalling 
molecules including eicosanoids such as prostacyclin 48, levels of which are known to be reduced 
in pulmonary hypertension, with replacement an established treatment option.  
Circulating levels of DHEA-S and its metabolites (androsterone, epiandrosterone and 
androstenediol/4-androsten-3beta, 17beta-diol disulfate) were reduced in PAH patients compared 
to healthy controls, consistent with a recent report of reduced circulating levels of DHEA-S in a 
small cohort of 23 male PAH patients compared to healthy controls 49. Differences in DHEA-S
between PAH and controls were independent of the more subtle effects of both gender and age 
(Fig. S3), and lower DHEA-S levels were independently associated with mortality. Treatment 
with DHEA or DHEA-S has repeatedly been shown to prevent and reverse pulmonary 
hypertension in experimental rat models 50, with clinical trials ongoing in COPD-associated 
pulmonary hypertension (ClinicalTrials.gov NCT00581087).  
 We found increased levels of a breakdown product of N1-acetylspermidine, acisoga. 
Other metabolites of polyamine metabolism (4-acetamidobutanoate and N-acetylputrescine) 
were increased in PAH in relation to bilirubin levels and were prognostic in 2 distinct PAH 
cohorts, independent of established prognostic markers. Several animal models of pulmonary 
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hypertension have demonstrated evidence of increased polyamine levels and metabolism  in lung 
tissue 51. Administration of monocrotaline to rats led to significantly increased levels of 
polyamines and the development of pulmonary hypertension and right ventricular hypertrophy, 
which could be prevented by the administration of an inhibitor of polyamine biosynthesis 52,
suggesting these molecules may be novel therapeutic targets. 
 In our study, we validated findings of elevated circulating tryptophan metabolites 14 with 
increased C-glycosyltryptophan and kynurenine in PAH patients compared to healthy controls, 
but changes in kynurenine were related to increased bilirubin levels and liver dysfunction. Levels 
of tryptophan and its other major metabolite, serotonin, were not significantly altered in our 
analysis. 
Limitations
The majority of patients included in this study were prevalent cases on established treatments. A 
sub-analysis was conducted with 40 incident cases and showed similar results. Corrections were 
also made for potential treatment effects in the main analyses, including PAH-specific and 
comorbidity-related therapies, as well as demographics and renal/hepatic function.
Patients and controls were sampled in the non-fasting state and information on insulin resistance 
was not available for all cases. Patients were also sampled from a peripheral vein. The stronger 
performance of discriminating models in discovery analyses suggests that optimisation could 
further improve their performance in distinct cohorts. Strongly correlated metabolites would not 
have been selected in the discriminant modelling, so each metabolite used in the final models 
may represent clusters of multiple metabolites. Evidence of tissue specificity and the source of 
circulating metabolites in pulmonary hypertension require further studies, for example, by 
transpulmonary sampling and direct measurements from tissue samples, to better localise the 
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source of informative metabolites. Plasma levels of metabolites may not reflect levels in the most 
important tissues, for example increased bile acid metabolites have been demonstrated in PAH 
lung tissue 53 but no differences were seen in circulating levels in our study. 
Summary and conclusions
Increased circulating modified nucleosides (N2,N2-dimethylguanosine, N1-methylinosine), TCA 
cycle intermediates (malate, fumarate), glutamate, fatty acid acylcarnitines and polyamine 
metabolites and decreased levels of steroids, sphingomyelins and phosphatidylcholines are a 
characteristic of patients with PAH that distinguish them from symptomatic patients without 
pulmonary hypertension. Improvements in circulating metabolite levels are associated with a 
better prognosis and could be used to monitor response to PAH treatments. Indeed, our results 
support the investigation of therapeutic strategies targeted at alterations in energy metabolism in 
PAH and suggest options for correcting translational regulation also merit further study. 
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Table 1. Cohort Characteristics. Means and standard deviations or counts are given. BMI, body mass index; NT-proBNP, N-terminal 
brain natriuretic peptide at time of sample; RDW, red cell distribution width; HC, healthy controls; DC, disease controls; COPD, 
chronic obstructive pulmonary disease; CAD, coronary artery disease; IHD, ischaemic heart disease; AF, atrial fibrillations; PDE5, 
phosphodiesterase 5; ERA, endothelin receptor antagonists; CCB, calcium channel blocker; ACE, angiotensin converting enzyme. 
Ethnicity is shown for subjects who self-declared.
Discovery Validation 1 Validation 2
HC         
(n=58)
DC         
(n=70)
PAH (19-70) 
(n=88)
PAH (>70)    
(n=28)
HC       
(n=63)
DC       
(n=69)
PAH        
(n=75)
PAH-2
(n=174)
Age at sampling, years 48+/-13.5 56.5+/-15.9 48.1+/-13.8 75.9+/-4.8 49.1+/-16.1 55.9+/-18.5 52+/-16.3 52+/-15
Sex, Female:Male (ratio) 38:20 (1.9:1) 48:22 (2.2:1) 61:27 (2.3:1) 19:9 (2.1:1) 40:23 (1.7:1) 48:21 (2.3:1) 52:23 (2.3:1) 127:47 (2.7:1)
Ethnicity, % non-Caucasian 32.5 56.9 17.0 14.8 38.1 44.1 18.6 8.1
BMI, kg/m2 30.5+/-10.5 27.9+/-6 28.7+/-8.2 27.9+/-5.7 26+/-4.1 27.4+/-5.9 30.1+/-7.2 29.2+/-7
Baseline haemodynamics at diagnosis
Pulmonary capillary wedge pressure, mmHg 11.6+/-4.5 11.9+/-6 12.1+/-4.6 10.8+/-3.5 10.8+/-4.9 9.4+/-3.8
Mean pulmonary artery pressure, mmHg 19.3+/-4.1 53.1+/-14.3 46.3+/-14.6 19.1+/-4.7 53.7+/-11.1 56.2+/-15.2
Pulmonary vascular resistance, Woods units 12.3+/-5.7 8.6+/-4.7 12.4+/-5.8 13+/-6.4
Mean right atrial pressure, mmHg 7.3+/-3.4 10.0+/-5.7 9.3+/-4.9 6.3+/-3.2 11.8+/-5.8 9.2+/-5.3
Cardiac output, L/min 4.4+/-1.7 4.5+/-1.8 4.0+/-1.7 4.0+/-1.3
Functional status and pathology
Six minute walk distance, m 279.4+/-153.4 197.9+/-158.7 271.3+/-169.5 334.8+/-119.0
WHO Functional Class, I/II/III/IV 2/11/65/10 0/2/23/1 0/7/52/9 2/24/119/18
RDW, % 14.8+/-2.1 15.0+/-1.1 16.0+/-2.9 14.7+/-3.3
NT-proBNP, pmol/L 735+/-882 1137+/-1123 895+/-1244
Creatinine, umol/L 76.3+/-21.8 81.2+/-29.1 107.6+/-35.7 87+/-40.6 92.7+/-32.6 89.9+/-25.1
Bilirubin, umol/L 13.9+/-13.9 15.6+/-10.7 12.4+/-8.5 16.3+/-22.8 17.2+/-10.4 12.1+/-9.0
Comorbidities
Asthma/COPD 17.1 11.4 11.1 11.6 17.1 17.6
Diabetes 8.6 17.0 48.1 13.0 24.3 14.2
CAD/IHD 10.0 12.5 37.0 11.6 12.9 8.3
AF/flutter 14.3 18.2 25.9 17.4 8.6 5.9
Systemic hypertension 22.9 19.3 77.8 36.2 22.9 17.2
Hypercholesterolaemia/lipidaemia 12.9 12.5 22.2 10.1 15.7 6.5
Drug therapy 
Anticoagulation 32.9 71.6 78.6 34.8 65.3 66.7
PDE5 inhibitors 0.0 65.9 67.9 0.0 48.0 77.8
ERA 0.0 48.0 30.8 0.0 33.8 64.3
Diuretics 12.9 37.5 75.0 21.7 53.3 54.4
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Aldosterone antagonists 7.1 31.8 21.4 1.4 34.7 8.2
Statins/lipid lowering drugs 25.7 22.7 57.1 33.3 24.0 24.0
CCB 10.0 14.8 28.6 24.6 14.7 21.1
Cardiac glycosides 7.1 17.0 14.3 8.7 21.3 9.4
Antidiabetic drugs 8.6 12.5 35.7 10.1 18.7 9.4
Prostanoids 0.0 9.1 0.0 0.0 6.7 33.3
Iron replacement therapy 4.3 13.6 25.0 5.8 4.0 10.5
ACE inhibitors 27.1 17.0 60.7 37.7 28.0 16.4
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Figure Legends
Figure 1. Analysis flow chart. Summary of analytical workflow showing numbers of metabolites 
that distinguish PAH from controls, and/or are prognostic in PAH.  
Figure 2. Metabolites which discriminate PAH and control subjects. (A) Average metabolite 
levels in PAH and control subjects for 20 metabolites found to significantly distinguish PAH and 
both healthy and disease controls, independent of potential confounders. Values plotted are z-
scores calculated based on mean and standard deviation of all healthy volunteers in study - 
negative values indicate metabolites at lower levels in patients versus healthy controls and 
positive values indicate higher levels of metabolites in patients. For the discovery analysis only 
data from PAH patients aged 19-70 is plotted and for the validation analysis all patients data are 
shown. (B) Network analysis of the same 20 metabolites based on second order correlations. 
Line thickness indicates strength of correlations (all p<0.0001). *probable metabolite identity, 
but unconfirmed (see methods). EPE,eicosapentaenoyl; DHE,docosahexaenoyl; 
DPE,docosapentaenoyl; DHEA-S,dehydroisoandrosterone sulphate; GPC, 
glycerophosphocholine; SM, sphingomyelin. 
Figure 3. Discriminant analysis models based on low numbers of metabolites distinguish PAH 
patients from controls. (A&C) Dotplots showing individual subjects’ model scores in healthy 
controls (HC), PAH patients, vasoresponders and disease controls (DC) in discovery and 
validation analyses. Metabolites were selected by logistic regression of PAH-HC (A) and PAH-
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DC (C) comparisons, respectively. (B&D) ROC curves showing performance of models in 
distinguishing PAH and HC (B) and DC (D) subjects. 
Figure 4. Prognostic metabolites independent of established risk factors. (A) Hazard ratios after 
correcting for creatinine and diuretic use of 36 metabolites which were prognostic in PAH 
patients independent of RDW, NT-proBNP and six minute walk distance. Hazard ratios indicate 
the risk of a change in each metabolite of 1 standard deviation, for ease of comparison. Patients 
of all ages were included in both discovery and validation survival analyses. (B) Network 
analysis of the same 36 metabolites based on second order correlations. Line thickness indicates 
strength of correlations (all p<0.0001). Red lines indicate negative correlations. *probable 
metabolite identity, but unconfirmed (see methods). EPE,eicosapentaenoyl; 
DHE,docosahexaenoyl; DPE,docosapentaenoyl; DHEA-S,dehydroisoandrosterone sulphate; 
GPC, glycerophosphocholine; GPE, glycerophosphoethanolamine. 
Figure 5. Hierarchical clustering of 19 discriminating and prognostic metabolites in PAH 
patients. (A) Venn diagram shows overlap between metabolites that discriminate PAH from 
healthy controls in all 3 cohorts, from logistic regression between PAH and healthy controls and 
prognostic metabolites in the discovery and first validation cohorts. (B) Clustering of the 19 
overlapping metabolites from A. is shown between healthy controls (n=58), PAH survivors 
(n=110, alive at 3 years post-sample) and non-survivors (n=24) in the discovery analysis. Red 
indicates metabolite levels that are increased (and blue levels that are decreased) in PAH versus 
controls. *probable metabolite identity, but unconfirmed (see methods), ‡metabolites also 
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distinguish PAH from disease controls. GPC, glycerophosphocholine; EPE, eicosapentaenoyl; 
SM, sphingomyelin. 
Figure 6. Analysis of serial samples. (A) ROC analysis of changes in metabolite levels and 
survival status at last follow-up. (B&D) Changes in individual patient metabolite levels, grouped 
by survival status at last follow-up. (C) Kaplan-Meier analysis illustrating survival over time in 
PAH patients divided into groups according to the changes in N-acetyl-methionine levels 
between serial samples.
Figure 7. Circulating angiogenin levels. (A) Plasma angiogenin levels determined by ELISA in 
healthy controls and PAH patients. (B) Scatter-plot of plasma N2,N2-dimethylguanosine versus 
plasma angiogenin in controls and PAH patients. Statistics shown are from Spearman’s Rank 
test.
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97 distinguish IPAH and 
healthy subjects in 3 
analyses (p<7.3e-5) 
53 independent of 
confounders – age, gender, 
ethnicity, BMI, liver/renal 
function, therapies (p<0.05) 
20 ‘PAH-specific’ –  
distinguish PAH from both 
healthy and disease 
controls, independent of 
confounders (p<0.05) 
1416 metabolites quantified, 187 
xenobiotics excluded, 686 metabolites 
quantified in >95% of subjects 
62 prognostic, independent 
of creatinine and diuretic 
use, in PAH patients in 2 
analyses (p<0.05) 
36 independent of 
established prognostic 
markers NT-proBNP, 6 
minute walk and RDW 
(p<0.05) 
100 either distinguish 
or prognostic 
16 both distinguishing 
and prognostic 
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Alanine and Aspartate
Polyamine
TCA Cycle
Fatty Acid, Acyl Choline
Fatty Acid, Dicarboxylate
Lysolipid
Mevalonate
Phospholipid
Sphingolipid
Purine, Adenine
Pyrimidine, Uracil
Unknown
Amino acid metabolism
Energy metabolism
Lipid metabolism
Nucleoside metabolism
Unidentified metabolites
N1-methylinosine 
N2,N2-dimethyl
guanosine 1-linoleoyl-2-EPE-
GPC (18:2/20:5)* 
1-DPE-GPC 
(22:5n3)* 
3-hydroxy-3-
methylglutarate 
malate 
SM (d18:1/20:0, 
d16:1/22:0)* 
SM 
(d18:1/22:1, 
d18:2/22:0, 
d16:1/24:1)* 
xanthine 
X - 13737
3-ureidopropionate 
X - 21796
acisoga 
SM (d18:2/23:0, 
d18:1/23:1, 
d17:1/24:1)* 
SM (d18:1/21:0, 
d17:1/22:0, 
d16:1/23:0)* 
octadecanedioate 
N-acetyl 
aspartate 
(NAA) 
palmitoylcholine 
X - 12688
-2 -1 0 1 2
Healthy
Disease
IPAH
Average metabolite levels in groups
-2 -1 0 1 2
Discovery Validation N2,N2-dimethylguanosine
N1-methylinosine
X - 12688
acisoga
malate
N-acetylaspartate (NAA)
xanthine
X - 13737
X - 21796
3-hydroxy-3-methylglutarate
octadecanedioate
3-ureidopropionate
SM (d18:2/23:0, d18:1/23:1, d17:1/24:1)*
1-linoleoyl-2-EPE-GPC (18:2/20:5)*
SM (d18:1/21:0, d17:1/22:0, d16:1/23:0)*
SM (d18:1/20:0, d16:1/22:0)*
1-docosapentaenoyl-GPC (22:5n3)*
1-arachidonoyl-GPC (20:4n6)*
SM (d18:1/22:1, d18:2/22:0, d16:1/24:1)*
palmitoylcholine
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
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C D 
A B 
Discovery 
Validation 
Validation-2 
Analysis AUC Sig. 95% CI 
Discovery 0.990 2E-22 0.979 - 1.000
Validation-1 0.950 2E-19 0.912 - 0.989
Validation-2 0.939 1E-37 0.914 - 0.964
Discovery 
Validation 
Validation-2 
Analysis AUC Sig. 95% CI 
Discovery 0.914 4E-18 0.869 - 0.958
Validation-1 0.723 2E-06 0.647 - 0.816
Validation-2 0.747 6E-14 0.692 - 0.801
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Alanine and Aspartate 
Histidine 
Met, Cys, SAM and Taur
Polyamine 
Acyl carnitine
Lysolipid
Phospholipid 
Steroid
Purine, Adenine
Pyrimidine, Uracil
Unknown
Amino acid metabolism Lipid metabolismNucleoside metabolism
Unidentified metabolites
1-linoleoyl-2-DHE-
GPC (18:2/22:6)* 
1-methylimida
-zoleacetate 
DHEA-S
N-acetyl
methionine 
N-acetyl
putrescine 
N1-methylinosine 
N2,N2-dimethyl-
guanosine 
N6-carbamoyl 
threonyladenosine 
phosphatidylcholine 
(18:0/20:5, 16:0/22:5n6)* 
urate 
X - 11429
X - 11564
X - 12688
X - 15503
X - 24020
X - 24513
X - 24527
pimeloyl/3-methyl 
adipoyl-carnitine 
1-linoleoyl-2-EPE-
GPC (18:2/20:5)* X - 12472 X - 24041
X - 24728
1-myristoyl-2-
DHE-GPC 
(14:0/22:6)* 
X - 12739
1-oleoyl-2-DPE-GPC 
(18:1/22:5n6)* 
1-EPE-GPE (20:5)* 
N6-succinyl 
adenosine 
1-myristoyl-2-
arachidonoyl-GPC         
(14:0/20:4)* 
1-palmitoyl-2-EPE-
GPC (16:0/20:5)* 
N-acetylalanine 
N-formylmethionine 
N1-methyl
adenosine 
4-acetamidobutanoate 
pseudouridine 
123
4
5
1:
2:
3:
4:
5:
.25 0.5 1 2 4 4 8 16 .25 0.5 1 2 4 4 16 64
N6-succinyladenosine
N6-carbamoylthreonyladenosine
N1-methylinosine
N2,N2-dimethylguanosine
X - 24020
N-acetylmethionine
X - 24513
1-methylimidazoleacetate
X - 12472
4-acetamidobutanoate
pimeloylcarnitine/3-methyladipoylcarnitine
X - 12739
N-acetylalanine
N1-methyladenosine
X - 24527
X - 12688
N-formylmethionine
pseudouridine
N-acetylputrescine
X - 24728
X - 15503
X - 11564
urate
X - 24411
X - 11429
dehydroisoandrosterone sulfate (DHEA-S)
1-linoleoyl-2-docosahexaenoyl-GPC (18:2/22:6)*
1-oleoyl-2-docosapentaenoyl-GPC (18:1/22:5n6)*
1-eicosapentaenoyl-GPE (20:5)*
1-myristoyl-2-arachidonoyl-GPC (14:0/20:4)*
phosphatidylcholine (18:0/20:5, 16:0/22:5n6)*
1-palmitoyl-2-eicosapentaenoyl-GPC (16:0/20:5)*
1-linoleoyl-2-eicosapentaenoyl-GPC (18:2/20:5)*
1-eicosapentaenoyl-GPC (20:5)*
1-myristoyl-2-docosahexaenoyl-GPC (14:0/22:6)*
X - 24041
Discovery Validation
Hazard ratios, after correcting for creatinine and diuretic use
A 
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A                   B 
 
 
 
 
 
 
 
 
 
 
 
C                   D 
Survivors       Non-survivors 
P<0.0001 
Survivors       Non-survivors 
P<0.0001 
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Metabolomic profiling methodology 
Samples were prepared with use of an automated MicroLab STAR system (Hamilton 
Company, Reno, NV, USA). For quality control (QC), a pooled sample from all experimental 
samples was used throughout the experiment, and a mixture of Metabolon QC standards were 
spiked into all experimental samples to monitor instrument performance and chromatographic 
alignment.  Samples were randomised prior to experimentation.  
 
Experiments were conducted on Waters Acuity ultra-performance liquid chromatography 
(UPLC) systems (Waters Corporation, Milford, MA, USA) using Thermo Scientific Q-
Exactive high resolution/accurate mass spectrometer interfaced with a heated electrospray 
 
Supplementary Materials 
ionization (HESI-II) source and Orbitrap mass analyser (Thermo Fisher Scientific, MA, 
USA).  
 
The analysis platform used four methods for Ultrahigh Performance Liquid Chromatography-
Tandem Mass Spectroscopy (UPLC-MS/MS) including a) positive ion mode electrospray 
ionisation (ESI), b) positive ion mode optimised for hydrophobic compounds, c) negative ion 
mode ESI and d) negative ionisation following elution from a hydrophilic interaction 
chromatography (HILIC) column. Scan time varied between methods and covered 70-
1000m/z.   
 
The resulting spectra were compared to the in-house Metabolon standard library using 
retention time, mass (m/z), adducts and MS/MS spectra. Analysis using this platform has 
been applied to measure metabolite levels in human plasma in control 1, 2 and disease 
populations 3, 4. All experiments and runs were conducted on the same day.    
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Table S1 (below). Metabolites distinguishing pulmonary arterial hypertension (PAH) from healthy (HC) and disease controls (DC). 97 metabolites 
that are significantly different between PAH and healthy controls in 3 cohorts (p<7.3e-5) are shown. Mean values are given and the data is scaled to the 
healthy control group. Significance from linear regression is shown (p value), and for metabolites with p>0.05 in PAH HC linear regression, the significant 
confounder is shown. Significance is also shown for Mann Whitney U test between PAH treatment naïve patients versus all HC, and PAH bone 
morphogenetic protein type 2 receptor (BMPR2) mutation carriers versus patients with no BMPR2 mutation. GPC, glycerophosphocholine. *probable 
metabolite identity, but unconfirmed (see methods).  
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  Group averages (z-score relative to healthy control levels) Statistics (p-values) and major confounders 
Metabolite Metabolic Pathway Discovery Validation1 Validation2 PAH BMPR2 Linear Regression Confounder Sub-analyses 
  HC DC 
PAH            
(19-70) 
HC DC PAH PAH2 Naïve Mutation 
HC vs               
PAH 
HC+DC 
vs            
PAH 
HC vs                        
PAH 
PAH 
Naïve 
vs HC 
BMPR2 
vs PAH 
Increased in PAH vs HC and DC (independent of confounders) 
N-acetylaspartate (NAA) Alanine & Aspartate  0.12 0.21 1.13 -0.11 0.64 1.32 0.87 1.47 0.93 2.3E-04 4.6E-03  3.0E-09 0.46 
octadecanedioate 
Fatty Acid, 
Dicarboxylate 
0.07 0.12 0.82 -0.07 0.34 0.93 0.35 0.95 0.43 1.5E-02 1.3E-02  7.3E-06 0.25 
3-hydroxy-3-methylglutarate Mevalonate  -0.07 0.57 0.89 0.07 0.57 1.15 0.76 1.20 0.75 3.5E-02 3.0E-02  1.6E-09 0.12 
acisoga Polyamine  -0.10 1.07 1.42 0.09 1.14 1.95 1.22 1.93 1.04 1.9E-04 1.5E-02  2.7E-11 2.9E-02 
N1-methylinosine 
Purine, Hypo- 
Xanthine/Inosine  
-0.22 0.58 1.50 0.20 0.86 1.85 1.29 1.78 1.50 8.1E-04 2.2E-02  1.5E-13 0.48 
xanthine 
Purine, Hypo- 
Xanthine/Inosine  
0.11 0.56 0.98 -0.10 0.62 1.06 1.00 1.35 1.16 2.0E-07 2.8E-03  3.4E-09 0.19 
N2,N2-dimethylguanosine Purine, Guanine  -0.11 0.83 1.56 0.10 1.15 2.00 1.39 1.95 1.36 1.1E-02 3.9E-02  2.2E-13 0.11 
3-ureidopropionate Pyrimidine, Uracil  -0.14 0.22 0.62 0.13 0.09 1.16 0.54 1.16 0.47 1.7E-02 9.0E-04  4.0E-09 0.36 
malate TCA Cycle -0.18 0.60 1.17 0.17 0.69 1.64 1.02 1.81 1.11 8.8E-04 9.1E-03  1.5E-14 0.35 
X - 12688 Unknown -0.11 1.01 1.50 0.10 1.14 1.70 1.26 1.76 0.99 4.9E-05 3.2E-02  6.4E-13 1.6E-02 
X - 13737 Unknown -0.05 0.19 0.97 0.05 0.38 1.03 0.91 1.15 0.94 1.8E-02 6.1E-03  1.9E-08 0.70 
X - 21796 Unknown 0.07 0.19 0.96 -0.07 0.44 1.06 0.73 1.33 0.83 5.0E-03 1.3E-02  1.9E-12 0.83 
Decreased in PAH vs HC and DC (independent of confounders)                         
palmitoylcholine 
Fatty Acid  (Acyl 
Choline) 
-0.05 -0.14 -1.33 0.05 -0.35 -0.73 -1.10 -0.94 -1.35 1.7E-03 8.3E-03  3.9E-05 4.8E-02 
1-arachidonoyl-GPC 
(20:4n6)* 
Lysolipid -0.08 -0.14 -1.09 0.08 -0.25 -0.74 -0.81 -0.81 -1.00 1.2E-02 3.2E-02  5.9E-05 0.27 
1-docosapentaenoyl-GPC 
(22:5n3)* 
Lysolipid -0.03 -0.17 -1.03 0.03 -0.21 -0.80 -0.84 -0.79 -1.02 9.0E-03 6.7E-03  1.6E-05 0.23 
1-linoleoyl-2-
eicosapentaenoyl-GPC 
(18:2/20:5)* 
Phospholipid  0.03 -0.39 -0.81 -0.03 -0.13 -1.13 -0.81 -1.16 -0.77 2.4E-02 1.2E-02  3.4E-08 0.68 
sphingomyelin (d18:1/20:0, 
d16:1/22:0)* 
Sphingolipid  0.05 -0.43 -1.02 -0.05 -0.38 -1.09 -1.05 -1.24 -0.93 1.3E-02 7.7E-03  1.2E-08 0.49 
sphingomyelin (d18:1/21:0, 
d17:1/22:0, d16:1/23:0)* 
Sphingolipid  0.03 -0.44 -0.89 -0.03 -0.32 -0.93 -0.76 -1.04 -0.83 2.7E-03 4.0E-02  1.4E-08 0.78 
sphingomyelin (d18:1/22:1, 
d18:2/22:0, d16:1/24:1)* 
Sphingolipid  0.07 -0.37 -1.09 -0.06 -0.32 -1.16 -1.03 -1.21 -1.12 2.6E-03 7.2E-04  1.8E-07 0.95 
sphingomyelin (d18:2/23:0, 
d18:1/23:1, d17:1/24:1)* 
Sphingolipid  0.04 -0.27 -0.63 -0.04 -0.17 -0.60 -0.54 -0.68 -0.66 4.9E-04 4.4E-02  1.0E-06 0.40 
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Increased in PAH vs HC (independent of confounders)                           
oleoyl ethanolamide Endocannabinoid 0.10 1.02 0.88 -0.09 1.15 1.02 0.52 0.84 0.29 1.3E-03 2.2E-01  5.6E-05 5.4E-03 
3-hydroxybutyrylcarnitine 
(1) 
Fatty Acid (Acyl 
Carnitine) 
0.02 0.52 0.91 -0.01 0.81 0.97 0.60 1.11 0.62 6.1E-05 1.1E-01  7.3E-09 4.5E-02 
3-hydroxybutyrylcarnitine 
(2) 
Fatty Acid (Acyl 
Carnitine) 
0.07 0.76 1.26 -0.06 1.02 1.24 0.90 1.49 0.81 4.7E-03 6.8E-01  3.4E-09 3.8E-02 
acetylcarnitine 
Fatty Acid (Acyl 
Carnitine) 
0.11 0.43 1.02 -0.10 0.77 0.88 0.59 0.94 0.56 1.2E-02 2.9E-01  5.7E-06 3.1E-02 
adipoylcarnitine 
Fatty Acid (Acyl 
Carnitine) 
-0.04 0.41 1.44 0.04 0.94 1.69 1.25 1.77 1.20 4.6E-02 3.9E-01  5.8E-10 0.09 
myristoleoylcarnitine* 
Fatty Acid (Acyl 
Carnitine) 
0.04 0.33 0.75 -0.04 0.64 0.85 0.53 0.91 0.37 1.6E-02 4.6E-01  6.2E-05 1.0E-02 
myristoylcarnitine 
Fatty Acid (Acyl 
Carnitine) 
0.01 0.46 0.81 -0.01 0.87 1.06 0.60 1.07 0.44 4.1E-02 9.5E-01  9.4E-06 1.1E-02 
oleoylcarnitine 
Fatty Acid (Acyl 
Carnitine) 
0.03 0.53 0.96 -0.03 0.83 1.39 1.20 1.22 0.87 1.8E-02 6.7E-01  3.2E-07 0.10 
palmitoleoylcarnitine* 
Fatty Acid (Acyl 
Carnitine) 
0.08 0.56 0.91 -0.07 0.90 1.23 0.85 1.14 0.69 8.5E-03 8.9E-01  7.9E-07 4.1E-02 
suberoylcarnitine 
Fatty Acid (Acyl 
Carnitine) 
0.10 0.55 1.40 -0.09 0.98 1.61 1.23 1.66 1.03 7.1E-03 3.5E-01  1.3E-09 2.9E-02 
glutamate Glutamate  0.16 0.47 1.13 -0.14 0.41 0.98 0.71 1.12 0.83 2.9E-02 1.4E-01  2.7E-07 0.98 
methionine sulfone 
Met, Cys, SAM & 
Tau 
-0.03 0.49 1.57 0.03 0.98 1.79 1.40 1.56 1.29 3.6E-02 4.9E-01  1.8E-09 0.14 
N-acetylmethionine 
Met, Cys, SAM & 
Tau 
-0.04 0.48 1.08 0.04 0.63 1.27 0.60 1.30 0.80 3.3E-03 1.6E-01  1.3E-09 0.22 
N-acetyltaurine 
Met, Cys, SAM & 
Tau 
0.07 0.56 1.02 -0.06 0.71 1.15 0.63 1.15 0.37 1.0E-03 7.1E-02  2.7E-07 9.7E-04 
N-formylmethionine 
Met, Cys, SAM & 
Tau 
-0.17 0.49 1.08 0.16 0.69 1.53 0.78 1.59 0.85 4.8E-02 3.0E-01  5.8E-10 0.10 
5,6-dihydrothymine 
Pyrimidine, 
Thymine  
-0.22 0.65 1.33 0.20 0.96 1.37 0.62 1.38 0.71 2.0E-04 6.7E-02  1.2E-08 0.15 
alpha-ketoglutarate TCA Cycle -0.04 0.45 0.68 0.04 0.71 1.57 1.13 1.61 1.14 2.2E-02 2.4E-01  2.6E-13 1.00 
fumarate TCA Cycle -0.15 0.30 0.65 0.13 0.45 1.14 0.56 1.23 0.31 2.1E-02 9.8E-02  3.5E-16 0.28 
C-glycosyltryptophan Tryptophan  -0.05 0.55 1.11 0.05 0.84 1.37 0.76 1.30 0.59 4.8E-02 3.9E-01  5.9E-07 4.7E-03 
X - 12127 Unknown 0.06 0.63 0.85 -0.06 0.61 1.05 0.67 1.07 0.73 1.6E-02 4.4E-01  1.6E-08 0.53 
X - 12472 Unknown -0.04 0.71 1.03 0.04 0.82 1.05 0.96 1.15 0.93 3.4E-03 8.2E-01  2.5E-07 0.59 
X - 12739 Unknown -0.09 0.87 1.02 0.08 1.11 1.12 0.99 1.18 0.97 2.4E-02 1.8E-01  6.8E-07 0.35 
X - 12824 Unknown -0.02 0.54 0.85 0.02 0.74 1.08 0.79 1.16 0.78 2.0E-02 6.8E-01  9.5E-08 0.44 
X - 17327 Unknown 0.03 0.66 0.86 -0.03 0.81 0.97 0.82 1.02 0.78 2.6E-02 7.0E-01  2.4E-06 0.34 
X - 21829 Unknown -0.07 0.44 0.82 0.06 0.65 1.24 0.66 1.41 0.62 2.5E-02 5.6E-01  2.4E-10 0.10 
X - 24307 Unknown 0.04 0.68 0.70 -0.04 0.52 1.18 0.97 1.09 0.94 6.9E-05 7.2E-02  1.2E-07 0.88 
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X - 24513 Unknown -0.10 0.67 1.05 0.09 0.92 1.44 0.98 1.30 0.77 2.4E-02 4.8E-01  1.4E-07 9.1E-03 
X - 24527 Unknown -0.08 0.86 1.11 0.08 1.17 1.22 1.06 1.22 0.94 3.5E-02 1.9E-01  2.2E-06 0.25 
X - 24678 Unknown 0.21 0.74 1.20 -0.19 0.62 1.34 0.70 1.33 0.83 4.9E-03 1.2E-01  3.6E-11 0.42 
X - 24766 Unknown -0.31 0.45 0.82 0.28 0.60 1.07 0.85 0.89 0.92 1.9E-02 3.9E-01  5.1E-07 0.78 
Decreased in PAH vs HC (independent of confounders)                           
asparagine Alanine & Aspartate  -0.06 -0.58 -0.88 0.05 -0.55 -1.00 -0.90 -1.22 -0.95 8.7E-04 8.5E-02  2.3E-07 0.64 
dehydroisoandrosterone 
sulfate (DHEA-S) 
Steroid -0.05 -1.17 -1.53 0.04 -0.95 -1.74 -1.77 -1.53 -1.56 2.5E-02 4.1E-01  1.3E-09 0.46 
X - 23765 Unknown 0.09 -0.50 -0.72 -0.08 -0.50 -0.90 -0.90 -1.02 -1.08 8.1E-04 2.0E-01  9.7E-07 0.15 
Increased in PAH vs HC                           
N-acetylalanine Alanine & Aspartate  -0.11 0.55 0.76 0.10 0.88 1.15 0.66 1.04 0.50 9.9E-01 2.3E-01 Diuretics 3.2E-05 1.6E-02 
N-acetylneuraminate Aminosugar  -0.11 0.50 0.93 0.11 0.63 0.88 0.47 0.76 0.28 7.4E-02 2.4E-01 Age 1.8E-04 1.0E-03 
erythronate* Aminosugar  -0.11 0.45 0.71 0.10 0.68 1.16 0.59 1.10 0.37 7.1E-01 6.5E-01 Bilirubin 5.4E-06 6.0E-03 
N-acetylglucosamine/N-
acetylgalactosamine 
Aminosugar  -0.14 0.50 0.72 0.13 0.89 0.95 0.58 0.62 0.54 1.0E-01 7.3E-01 Gender 1.8E-03 4.4E-02 
gulonic acid* 
Ascorbate & 
Aldarate  
-0.08 0.49 0.61 0.07 0.57 0.79 0.61 0.81 0.47 8.5E-01 5.3E-01 Age 4.5E-05 2.8E-02 
palmitoylcarnitine 
Fatty Acid (Acyl 
Carnitine) 
-0.03 0.49 0.91 0.03 1.03 1.28 0.95 1.23 0.90 6.0E-02 9.2E-01 Bilirubin 1.6E-07 0.43 
malonylcarnitine Fatty Acid Synthesis 0.00 0.20 0.56 0.00 0.29 0.94 0.48 0.96 0.57 1.3E-01 3.8E-02 Bilirubin 3.8E-09 0.53 
N-acetylserine 
Glycine, Serine & 
Threonine  
-0.16 0.63 1.00 0.15 1.04 1.49 0.97 1.38 0.85 5.2E-01 4.0E-01 Bilirubin 6.9E-08 0.05 
N-acetylthreonine 
Glycine, Serine & 
Threonine  
-0.22 0.31 0.68 0.20 0.64 0.99 0.55 1.10 0.47 6.5E-01 9.7E-01 Bilirubin 4.4E-07 2.0E-02 
1-methylimidazoleacetate Histidine  -0.05 0.52 0.86 0.04 0.50 1.32 0.86 1.02 0.74 6.0E-02 9.5E-02 Age 7.9E-07 0.08 
imidazole propionate Histidine  -0.21 0.44 0.84 0.19 0.71 0.99 0.79 0.98 0.84 1.4E-01 8.1E-01 Bilirubin 1.1E-07 0.54 
quinolinate 
Nicotinate & 
Nicotinamide  
-0.11 0.46 0.76 0.10 0.68 1.19 0.86 0.95 0.58 6.0E-01 5.0E-01 Bilirubin 1.8E-04 3.8E-02 
vanillylmandelate (VMA) 
Phenylalanine & 
Tyrosine  
-0.21 0.35 1.00 0.19 0.37 1.52 0.83 1.75 0.96 2.3E-01 1.5E-02 Age 6.3E-12 0.37 
4-acetamidobutanoate Polyamine  -0.10 0.72 1.22 0.09 0.90 1.93 1.26 1.83 1.19 8.6E-01 7.0E-01 Bilirubin 1.0E-11 0.15 
N-acetylputrescine Polyamine  -0.16 0.66 0.84 0.15 0.72 1.32 0.66 0.93 0.53 5.8E-01 6.2E-01 Bilirubin 3.0E-06 3.8E-02 
N6-carbamoylthreonyl 
adenosine 
Purine, Adenine  -0.12 0.58 1.04 0.11 0.90 1.49 1.06 1.31 0.92 1.7E-01 4.5E-01 Age 8.4E-09 4.6E-02 
N1-methyladenosine Purine, Adenine  -0.21 0.70 0.94 0.19 0.91 1.26 0.65 1.03 0.46 8.6E-01 1.4E-01 Bilirubin 2.4E-05 4.4E-03 
N6-succinyladenosine Purine, Adenine  -0.06 0.38 0.63 0.05 0.43 0.86 0.50 0.94 0.44 1.5E-01 2.7E-01 Bilirubin 1.2E-09 2.7E-03 
N4-acetylcytidine 
Pyrimidine, 
Cytidine  
0.07 0.55 1.31 -0.06 0.77 1.50 1.22 1.33 1.19 2.7E-01 6.7E-01 Bilirubin 1.3E-08 0.47 
orotidine Pyrimidine, Orotate  -0.11 0.58 1.07 0.10 0.95 1.27 0.96 1.27 0.83 2.8E-01 5.3E-01 Bilirubin 1.4E-08 0.08 
pseudouridine Pyrimidine, Uracil  -0.08 0.77 1.22 0.08 1.05 1.66 1.17 1.68 0.97 1.5E-01 8.6E-01 Bilirubin 5.2E-11 1.4E-02 
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kynurenine Tryptophan  -0.14 0.29 1.00 0.13 0.57 1.37 0.77 1.44 0.68 5.6E-01 3.3E-01 Bilirubin 1.2E-08 0.07 
X - 12100 Unknown -0.13 0.49 1.04 0.12 0.85 1.26 0.88 1.28 0.75 1.3E-01 4.6E-01 Age 9.8E-08 0.06 
X - 11564 Unknown -0.13 0.51 0.94 0.12 0.90 1.48 0.83 1.43 0.73 9.6E-01 8.8E-01 Bilirubin 3.5E-07 0.06 
X - 12026 Unknown -0.16 0.69 1.58 0.14 1.01 2.01 1.36 2.20 1.26 6.9E-01 7.7E-01 Bilirubin 3.8E-12 0.07 
X - 12117 Unknown -0.12 0.66 1.18 0.11 0.98 1.55 1.35 1.50 1.20 6.7E-01 3.6E-01 Bilirubin 7.7E-09 0.19 
X - 15503 Unknown -0.17 0.28 1.04 0.15 0.70 1.64 1.06 1.68 1.33 6.3E-01 5.6E-02 Bilirubin 2.5E-10 0.63 
X - 11429 Unknown -0.07 0.88 1.52 0.07 1.31 1.98 1.45 1.88 1.18 9.1E-02 8.4E-01 Diuretics 3.4E-10 2.0E-02 
X - 21736 Unknown -0.06 0.33 1.04 0.06 0.59 1.46 0.92 1.57 0.95 2.7E-01 3.5E-01 Diuretics 1.1E-10 0.42 
pro-hydroxy-pro 
Urea cycle; 
Arginine & Proline  
-0.03 0.32 0.87 0.03 0.51 1.24 0.90 1.07 0.98 9.6E-01 6.9E-01 Diuretics 2.9E-06 0.95 
Decreased in PAH vs HC                         
histidine Histidine  -0.07 -0.74 -1.57 0.06 -0.91 -1.89 -1.71 -1.78 -1.60 6.1E-02 8.2E-03 Prostanoids 1.2E-11 4.2E-01 
1-linoleoyl-GPC (18:2) Lysolipid -0.10 -0.59 -1.22 0.09 -0.51 -1.14 -1.12 -1.33 -1.10 5.8E-02 2.4E-02 Bilirubin 1.3E-07 5.2E-01 
2-linoleoyl-GPC (18:2)* Lysolipid -0.11 -0.55 -1.23 0.10 -0.42 -0.97 -1.09 -1.35 -1.15 9.4E-02 2.9E-02 Bilirubin 4.5E-08 9.6E-01 
1-dihomo-linoleoyl-GPC 
(20:2)* 
Lysolipid 0.00 -0.39 -0.95 0.00 -0.49 -0.86 -1.14 -0.98 -1.30 2.4E-01 4.3E-01 Statins 5.5E-05 1.2E-01 
1-(1-enyl-palmitoyl)-2-
linoleoyl-GPC (P-
16:0/18:2)* 
Plasmalogen 0.01 -0.38 -1.06 -0.01 -0.17 -1.13 -0.98 -1.28 -1.08 2.3E-01 1.5E-01 PDE5 inhib 5.1E-08 9.4E-01 
behenoyl sphingomyelin 
(d18:1/22:0)* 
Sphingolipid  0.02 -0.22 -0.75 -0.01 -0.20 -0.71 -0.92 -0.78 -0.77 1.4E-01 3.0E-02 Gender 3.6E-06 8.4E-01 
4-androsten-3beta,17beta-
diol disulfate (1) 
Steroid -0.04 -0.64 -0.87 0.03 -0.47 -0.81 -1.14 -0.55 -1.06 2.4E-01 5.4E-01 Gender 4.0E-03 6.8E-01 
4-androsten-3beta,17beta-
diol monosulfate (1) 
Steroid -0.01 -0.85 -1.15 0.01 -0.68 -1.30 -1.40 -1.18 -1.32 5.6E-02 3.7E-01 Gender 5.8E-07 9.3E-01 
androsterone sulfate Steroid -0.02 -0.70 -1.33 0.02 -0.69 -1.40 -1.40 -1.14 -1.33 1.5E-01 2.0E-01 Gender 4.6E-06 7.3E-01 
epiandrosterone sulfate Steroid -0.02 -0.86 -1.42 0.01 -0.72 -1.50 -1.49 -1.23 -1.40 1.3E-01 3.9E-01 Gender 1.1E-06 6.4E-01 
pregn steroid monosulfate* Steroid -0.08 -0.83 -0.88 0.07 -0.68 -0.93 -1.04 -0.71 -0.84 1.0E-01 6.7E-01 Gender 3.3E-04 2.6E-01 
X - 23749 Unknown 0.04 -0.16 -1.10 -0.03 -0.34 -1.05 -1.12 -0.94 -1.41 2.0E-01 2.7E-01 BMI 5.4E-05 0.02 
arginine 
Urea cycle; 
Arginine & Proline  
-0.05 -0.67 -1.05 0.04 -0.79 -1.40 -1.47 -1.80 -1.32 1.1E-01 3.1E-01 DM drugs 2.1E-11 6.5E-01 
homoarginine 
Urea cycle; 
Arginine & Proline  
-0.05 -0.70 -0.91 0.05 -0.59 -1.13 -1.06 -1.11 -0.86 5.1E-02 2.1E-01 Ethnicity 4.8E-07 7.6E-02 
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Table S1. Metabolites distinguishing pulmonary arterial hypertension (PAH) from healthy (HC) and disease controls (DC). 97 metabolites that are 
significantly different between PAH and healthy controls in 3 cohorts (p<7.3e-5) are shown. Mean values are given and the data is scaled to the healthy 
control group. Significance from linear regression is shown (p value), and for metabolites with p>0.05 in PAH HC linear regression, the significant 
confounder is shown. Significance is also shown for Mann Whitney U test between PAH treatment naïve patients versus all HC, and PAH bone 
morphogenetic protein type 2 receptor (BMPR2) mutation carriers versus patients with no BMPR2 mutation. GPC, glycerophosphocholine. *probable 
metabolite identity, but unconfirmed (see methods).  
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Table S2. (below) Survival analysis. 
Metabolite Metabolic Pathway Discovery  Validation1 
   Hazard Ratio  Sig Hazard Ratio Sig 
Higher value indicates mortality. Independent of established prognostic markers 
N-acetylalanine Alanine and Aspartate  2.02 (1.22-3.36) 6.43E-03 2.08 (1.12-3.86) 2.04E-02 
pimeloylcarnitine/3-methyladipoylcarnitine Fatty Acid (Acyl Carnitine) 2.16 (1.28-3.66) 4.03E-03 2.52 (1.24-5.10) 1.04E-02 
1-methylimidazoleacetate Histidine  2.26 (1.37-3.73) 1.43E-03 1.74 (1.03-2.93) 3.93E-02 
N-acetylmethionine Methionine, Cysteine, SAM and Taurine  2.36 (1.41-3.96) 1.16E-03 2.29 (1.18-4.43) 1.44E-02 
N-formylmethionine Methionine, Cysteine, SAM and Taurine  1.79 (1.20-2.68) 4.50E-03 1.98 (1.20-3.25) 7.15E-03 
4-acetamidobutanoate Polyamine  2.20 (1.45-3.35) 2.19E-04 2.02 (1.30-3.14) 1.83E-03 
N-acetylputrescine Polyamine  1.74 (1.04-2.91) 3.54E-02 2.92 (1.51-5.66) 1.50E-03 
N1-methylinosine Purine , (Hypo)Xanthine/Inosine  2.82 (1.74-4.57) 2.42E-05 1.73 (1.09-2.77) 2.11E-02 
urate Purine , (Hypo)Xanthine/Inosine  1.61 (1.06-2.42) 2.43E-02 2.14 (1.26-3.64) 4.73E-03 
N6-succinyladenosine Purine , Adenine  3.89 (1.40-10.82) 9.18E-03 8.31 (1.94-35.54) 4.29E-03 
N6-carbamoylthreonyladenosine Purine , Adenine  3.10 (1.60-6.00) 8.04E-04 2.08 (1.08-4.00) 2.81E-02 
N1-methyladenosine Purine , Adenine  1.94 (1.25-3.01) 2.92E-03 1.93 (1.12-3.32) 1.75E-02 
N2,N2-dimethylguanosine Purine , Guanine  2.53 (1.57-4.08) 1.35E-04 1.86 (1.14-3.03) 1.25E-02 
pseudouridine Pyrimidine , Uracil  1.78 (1.07-2.94) 2.54E-02 2.75 (1.48-5.12) 1.45E-03 
X - 24020 Unknown 2.47 (1.42-4.30) 1.36E-03 1.84 (1.00-3.39) 4.94E-02 
X - 24513 Unknown 2.34 (1.28-4.29) 5.92E-03 2.18 (1.11-4.29) 2.34E-02 
X - 12472 Unknown 2.24 (1.44-3.47) 3.11E-04 1.57 (1.00-2.46) 4.97E-02 
X - 12739 Unknown 2.07 (1.41-3.04) 2.07E-04 1.56 (1.06-2.28) 2.28E-02 
X - 24527 Unknown 1.85 (1.38-2.48) 4.09E-05 1.43 (1.03-1.99) 3.12E-02 
X - 12688 Unknown 1.81 (1.23-2.68) 2.83E-03 2.02 (1.27-3.19) 2.80E-03 
X - 24728 Unknown 1.70 (1.09-2.64) 1.96E-02 2.04 (1.09-3.79) 2.50E-02 
X - 15503 Unknown 1.67 (1.11-2.52) 1.38E-02 1.51 (1.03-2.22) 3.48E-02 
X - 11564 Unknown 1.62 (1.10-2.38) 1.49E-02 1.60 (1.03-2.47) 3.51E-02 
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X - 24411 Unknown 1.54 (1.04-2.27) 3.05E-02 2.16 (1.32-3.54) 2.17E-03 
X - 11429 Unknown 1.47 (1.05-2.06) 2.65E-02 1.79 (1.18-2.71) 5.76E-03 
Lower value indicates mortality. Independent of established prognostic markers 
1-eicosapentaenoyl-GPE (20:5)* Lysolipid 0.60 (0.43-0.84) 2.65E-03 0.62 (0.39-1.00) 4.98E-02 
1-eicosapentaenoyl-GPC (20:5)* Lysolipid 0.47 (0.31-0.73) 6.30E-04 0.50 (0.31-0.82) 6.05E-03 
1-linoleoyl-2-docosahexaenoyl-GPC (18:2/22:6)* Phospholipid  0.64 (0.46-0.89) 7.40E-03 0.65 (0.47-0.91) 1.27E-02 
1-oleoyl-2-docosapentaenoyl-GPC (18:1/22:5n6)* Phospholipid  0.64 (0.47-0.87) 4.11E-03 0.62 (0.43-0.90) 1.06E-02 
1-myristoyl-2-arachidonoyl-GPC (14:0/20:4)* Phospholipid  0.57 (0.39-0.83) 3.68E-03 0.68 (0.48-0.96) 2.66E-02 
phosphatidylcholine (18:0/20:5, 16:0/22:5n6)* Phospholipid  0.54 (0.37-0.77) 7.30E-04 0.42 (0.25-0.72) 1.44E-03 
1-palmitoyl-2-eicosapentaenoyl-GPC (16:0/20:5)* Phospholipid  0.53 (0.37-0.75) 4.11E-04 0.43 (0.26-0.74) 1.96E-03 
1-linoleoyl-2-eicosapentaenoyl-GPC (18:2/20:5)* Phospholipid  0.48 (0.33-0.70) 1.38E-04 0.60 (0.41-0.88) 8.59E-03 
1-myristoyl-2-docosahexaenoyl-GPC (14:0/22:6)* Phospholipid  0.47 (0.31-0.72) 4.84E-04 0.49 (0.29-0.81) 5.62E-03 
dehydroisoandrosterone sulfate (DHEA-S) Steroid 0.71 (0.52-0.97) 3.19E-02 0.55 (0.33-0.91) 2.06E-02 
X - 24041 Unknown 0.46 (0.29-0.72) 6.88E-04 0.61 (0.38-0.99) 4.45E-02 
Higher value indicates mortality 
hexadecanedioate Fatty Acid, Dicarboxylate 1.53 (1.09-2.14) 1.40E-02 1.67 (1.16-2.41) 5.58E-03 
N-acetyltaurine Methionine, Cysteine, SAM and Taurine  1.97 (1.16-3.35) 1.19E-02 2.24 (1.13-4.43) 2.05E-02 
3-hydroxy-3-methylglutarate Mevalonate  1.68 (1.03-2.74) 3.78E-02 2.08 (1.02-4.23) 4.40E-02 
vanillylmandelate (VMA) Phenylalanine and Tyrosine  1.48 (1.06-2.06) 2.02E-02 1.58 (1.06-2.34) 2.38E-02 
N-acetyl-beta-alanine Pyrimidine , Uracil  1.54 (1.08-2.21) 1.80E-02 1.65 (1.18-2.32) 3.65E-03 
fumarate TCA Cycle 1.70 (1.00-2.88) 4.97E-02 2.57 (1.09-6.06) 3.09E-02 
N2,N5-diacetylornithine Urea cycle; Arginine and Proline  2.15 (1.27-3.63) 4.37E-03 2.15 (1.13-4.09) 1.95E-02 
Lower value indicates mortality 
valine Leucine, Isoleucine and Valine  0.66 (0.49-0.89) 6.80E-03 0.68 (0.48-0.95) 2.21E-02 
1-docosahexaenoyl-GPE (22:6)* Lysolipid 0.68 (0.49-0.94) 1.86E-02 0.54 (0.34-0.85) 8.27E-03 
1-dihomo-linolenoyl-GPC (20:3n3 or 6)* Lysolipid 0.57 (0.41-0.79) 7.43E-04 0.71 (0.53-0.96) 2.82E-02 
1-docosahexaenoyl-GPC (22:6)* Lysolipid 0.54 (0.35-0.81) 3.17E-03 0.57 (0.35-0.93) 2.32E-02 
phosphatidylcholine (16:0/22:5n3, 18:1/20:4)* Phospholipid  0.68 (0.48-0.96) 2.64E-02 0.59 (0.36-0.98) 4.16E-02 
1-stearoyl-2-docosahexaenoyl-GPE (18:0/22:6)* Phospholipid  0.64 (0.47-0.88) 5.99E-03 0.52 (0.32-0.85) 8.73E-03 
1-palmitoleoyl-2-docosahexaenoyl-GPC (16:1/22:6)* Phospholipid  0.62 (0.43-0.90) 1.09E-02 0.50 (0.28-0.88) 1.67E-02 
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1-pentadecanoyl-2-docosahexaenoyl-GPC (15:0/22:6)* Phospholipid  0.62 (0.42-0.90) 1.30E-02 0.34 (0.17-0.68) 1.96E-03 
1-stearoyl-2-docosahexaenoyl-GPC (18:0/22:6) Phospholipid  0.60 (0.42-0.87) 7.16E-03 0.45 (0.27-0.76) 2.76E-03 
1-stearoyl-2-docosapentaenoyl-GPC (18:0/22:5n3)* Phospholipid  0.58 (0.41-0.82) 2.11E-03 0.50 (0.30-0.83) 8.18E-03 
1-palmitoyl-2-dihomo-linolenoyl-GPC (16:0/20:3n3 or 6)* Phospholipid  0.58 (0.38-0.88) 9.67E-03 0.54 (0.35-0.84) 6.47E-03 
1-(1-enyl-stearoyl)-2-docosahexaenoyl-GPC (P-18:0/22:6)* Plasmalogen 0.56 (0.37-0.85) 6.20E-03 0.57 (0.33-0.98) 4.06E-02 
1-(1-enyl-stearoyl)-2-docosahexaenoyl-GPE (P-18:0/22:6)* Plasmalogen 0.55 (0.37-0.82) 3.45E-03 0.49 (0.27-0.91) 2.31E-02 
1-(1-enyl-palmitoyl)-2-docosahexaenoyl-GPC (P-16:0/22:6)* Plasmalogen 0.54 (0.37-0.79) 1.31E-03 0.53 (0.32-0.87) 1.30E-02 
1-(1-enyl-palmitoyl)-2-docosahexaenoyl-GPE (P-16:0/22:6)* Plasmalogen 0.49 (0.34-0.71) 1.63E-04 0.47 (0.26-0.82) 8.30E-03 
sphingomyelin (d18:2/14:0, d18:1/14:1)* Sphingolipid  0.73 (0.53-1.00) 4.83E-02 0.48 (0.30-0.77) 2.36E-03 
sphingomyelin (d18:1/20:0, d16:1/22:0)* Sphingolipid  0.60 (0.41-0.87) 6.60E-03 0.57 (0.35-0.93) 2.32E-02 
sphingomyelin (d18:1/22:1, d18:2/22:0, d16:1/24:1)* Sphingolipid  0.59 (0.42-0.83) 2.51E-03 0.53 (0.33-0.85) 7.63E-03 
behenoyl sphingomyelin (d18:1/22:0)* Sphingolipid  0.42 (0.27-0.64) 5.94E-05 0.47 (0.27-0.82) 7.42E-03 
 
Table S2. Survival analysis in PAH. 62 metabolites significantly different between PAH survivors and non-survivors in discovery and validation1 cohorts 
(p<0.05) are shown. Hazard ratio and significance (Sig) is shown from Cox regression analysis. Hazard ratios shown are for 1 standard deviation change in 
each metabolite for ease of comparison. Metabolites which are also independent of established prognostic markers in the discovery cohort are also shown. 
*probable metabolite identity, but unconfirmed (see methods). GPC, glycerophosphocholine; GPE, glycerophosphoethanolamine. 
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Pathway Result Metabolite 
HC v 
PAH 
Prog- 
nosis 
Fatty Acid 
Metabolism(Acyl 
Carnitine) 
4.5E-05 3-hydroxybutyrylcarnitine (1) 6E-05 0.3499 
 
pimeloylcarnitine/3-
methyladipoylcarnitine NA 0.0006 
 suberoylcarnitine 0.0071 0.0044 
 3-hydroxybutyrylcarnitine (2) 0.0047 0.0046 
 palmitoleoylcarnitine* 0.0085 0.3042 
 adipoylcarnitine 0.0464 0.0106 
 acetylcarnitine 0.0118 0.141 
 myristoleoylcarnitine* 0.0165 0.6142 
 oleoylcarnitine 0.0176 0.0598 
 myristoylcarnitine 0.0412 0.2631 
 palmitoylcarnitine 0.0604 0.1959 
 linoleoylcarnitine* NA 0.0615 
 hexanoylcarnitine NA 0.5981 
 stearoylcarnitine NA 0.6611 
 octanoylcarnitine NA 0.8074 
 laurylcarnitine NA 0.8641 
 decanoylcarnitine NA 0.912 
 cis-4-decenoyl carnitine NA 0.9541 
Polyamine Metabolism 0.01079 N-acetylputrescine 0.5825 2E-05 
 4-acetamidobutanoate 0.8618 3E-05 
 acisoga 0.0002 0.0003 
 5-methylthioadenosine (MTA) NA 0.0433 
Alanine and Aspartate 
Metabolism 
0.02412 N-acetylaspartate (NAA) 0.0002 0.2634 
 asparagine 0.0009 0.9422 
 N-acetylalanine 0.9901 0.009 
 alanine NA 0.6529 
 aspartate NA 0.9677 
Purine Metabolism, 
(Hypo)Xanthine/Inosine 
containing 
0.04317 xanthine 2E-07 0.438 
 urate NA 0.0004 
 N1-methylinosine 0.0008 0.0144 
 AICA ribonucleotide NA 0.0066 
 allantoin NA 0.0934 
 hypoxanthine NA 0.6652 
Purine Metabolism, 
Adenine containing 
0.04317 N6-carbamoylthreonyladenosine 0.1735 7E-05 
 N6-succinyladenosine 0.1452 0.0005 
 N1-methyladenosine 0.8632 0.0006 
 adenine NA 0.4835 
 adenosine NA 0.5677 
 
adenosine 5'-monophosphate 
(AMP) NA 0.5988 
Pyrimidine Metabolism, 
Uracil containing 
0.04317 pseudouridine 0.1506 6E-05 
 N-acetyl-beta-alanine NA 0.0002 
 3-ureidopropionate 0.0175 0.0024 
 uridine NA 0.2684 
 5-methyluridine (ribothymidine) NA 0.5196 
 beta-alanine NA 0.8665 
    
    
    
Table S3. Pathway enrichment analysis results. Pathways analysed and enrichment p-values are 
given, as well as metabolites within each pathway and significance values from tests used to select 
metabolites considered to be disease-associated. HC v PAH, significance of PAH on metabolite levels 
after controlling for potential confounders by linear regression; Prognosis, weakest significance of 
metabolite association with survival by Cox analysis in discovery or validation cohorts. *probable 
metabolite identity, but unconfirmed (see methods).  
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Metabolite Area Sig. 95% CI 
3-hydroxy-3-methylglutarate 0.75 2.05E-04 0.63 - 0.86 
3-hydroxybutyrylcarnitine (2) 0.67 1.10E-02 0.54 - 0.79 
4-acetamidobutanoate 0.67 8.40E-03 0.56 - 0.79 
5,6-dihydrothymine 0.67 1.04E-02 0.55 - 0.79 
acetylcarnitine 0.65 2.80E-02 0.52 - 0.77 
C-glycosyltryptophan 0.66 1.82E-02 0.53 - 0.78 
fumarate 0.67 1.01E-02 0.55 - 0.79 
hexadecanedioate 0.65 2.32E-02 0.52 - 0.78 
malate 0.69 3.32E-03 0.58 - 0.81 
N1-methyladenosine 0.69 3.62E-03 0.57 - 0.81 
N2,N2-dimethylguanosine 0.69 4.70E-03 0.57 - 0.80 
N-acetylalanine 0.67 1.01E-02 0.55 - 0.79 
N-acetylmethionine 0.76 6.94E-05 0.66 - 0.87 
N-acetylputrescine 0.69 4.07E-03 0.57 - 0.81 
N-acetyltaurine 0.68 6.40E-03 0.56 - 0.80 
N-formylmethionine 0.67 8.63E-03 0.56 - 0.79 
X - 11564 0.65 2.16E-02 0.53 - 0.77 
X - 12127 0.65 2.43E-02 0.53 - 0.77 
X - 12472 0.65 2.32E-02 0.53 - 0.77 
X - 12688 0.68 5.26E-03 0.57 - 0.80 
X - 12739 0.68 7.75E-03 0.56 - 0.79 
X - 13737 0.66 1.45E-02 0.54 - 0.78 
X - 15503 0.68 5.89E-03 0.56 - 0.80 
X - 21796 0.70 3.03E-03 0.59 - 0.80 
X - 24020 0.67 1.15E-02 0.55 - 0.78 
X - 24527 0.67 8.63E-03 0.55 - 0.79 
X - 24766 0.67 1.07E-02 0.55 - 0.78 
 
Table S4. ROC analysis of serial metabolite measurements. Area under the curve values for the 
association between metabolite level changes (i.e. sample 1 subtracted from sample 2) and survival 
during follow-up are shown for significantly associated metabolites. *probable metabolite identity, 
but unconfirmed (see methods). 
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 Controls PAH (19-70) PAH (>70) 
 n=30 n=69 n=8 
Female:Male ratio 2.0 2.3 3.0 
Age 48.5 +/- 13.1 48.3 +/- 14.1 75.6 +/- 8.1 
Angiogenin conc., ng/ml 360 +/- 110.3 479.7 +/- 176.6 554.9 +/- 234.2 
N2,N2-dimethylguanosine -0.1 +/- 1 1.6 +/- 1.2 2.7 +/- 1.4 
 
Table S5. Demographics and circulating factor levels in subjects used for angiogenin study. 
Mean +/- standard deviation is shown for continuous variables.  
 
 
 
 
 
Fig. S1. Metabolite levels in BMRP2 mutation carriers. (A) Average metabolite levels in PAH 
BMPR2 mutation carriers, non-carriers and control subjects for 20 metabolites found to significantly 
distinguish PAH and both healthy and disease controls, independent of potential confounders. (B) 
Correlation of average metabolite levels in BMPR2 mutation carriers and non-carriers relative to 
controls for 53 metabolites that distinguish PAH from healthy controls, independent of potential 
A B
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confounders.  Values plotted are z-scores calculated based on mean and standard deviation of all 
healthy volunteers in study - negative values indicate metabolites at lower levels in patients versus 
healthy controls and positive values indicate higher levels of metabolites in patients. *probable 
metabolite identity, but unconfirmed (see methods). 
 
 
Fig. S2– Survival analysis of PAH patients. (A) Receiver operating characteristic (ROC) curve for 
N2,N2-dimethylguanosine in the discovery cohort at 3 years of follow-up. The optimal cut-off for 
high/low risk levels of N2,N2-dimethylguanosine was derived from this for B&C. Kaplan Meier 
survival estimates in PAH patients in the discovery (B) and first validation (C) cohorts.  
 
N at risk
<1.83 SD 123 120 108 79 25
>1.83 SD 63 58 46 31 15
N at risk
<1.83 SD 79 73 57 36 24
>1.83 SD 65 56 39 21 13
A B
C
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Fig. S3. Dehydroisoandrosterone-sulphate (DHEA-S). Plasma DHEA-S levels in the discovery 
cohort are shown for healthy controls (HC) and PAH (19-70) with (A) separation by gender and (B) 
against age.  
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